Luitpold Animal Health, manufacturers of Adequan products, issued an update June 27 on the drug’s current and future availability. The company announced in May that they expected supply shortages due to factory renovations at their Shirley, N.Y., facility.
"Luitpold’s New York facility has undergone significant renovations and upgrades to meet enhanced quality standards and address observations made by the U.S. Food and Drug Administration (FDA)," the June 27 statement read. "These renovations required cessation of manufacturing and affected Luitpold’s ability to release product. This has resulted in shortages in the marketplace. Luitpold has worked in recent months to optimally allocate inventory and manage the limited remaining supply, which has now been depleted.
"Luitpold remains committed to resuming its manufacture and release of Adequan products," the statement continued. "The company’s latest expectations for reestablishing Adequan supply to the market is estimated to be first quarter 2014; however, this hinges upon completion of a successful inspection by the FDA."
Adequan (polysulfated glycosaminoglycan) was approved by the FDA for equine use in 1984, and is designed to treat non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal (knee) and hock joints in horses.
The statement noted that the company developed a dedicated webpage on their website where interested indiv